搜尋結果
6 小時前 · Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response.
19 小時前 · Updated Novavax COVID-19 vaccine available free under Singapore's national vaccination programme MOH said that during Singapore’s previous JN.1 wave, the incidence rate of COVID-19 ...
19 小時前 · Novavax as it makes a more traditional protein-based shot that takes longer to manufacture. Vaccines based on messenger RNA (mRNA), like those from Moderna, or Pfizer and its partner BioNTech ...
4 小時前 · XBI, NVAX, INSM, MRNA: ETF Outflow Alert. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF ...
19 小時前 · Novavax, Inc. ist ein Biotechnologieunternehmen, das Impfstoffe zur Vorbeugung schwerer Infektionskrankheiten erforscht, entwickelt und vermarktet. Das Unternehmen bietet eine differenzierte Impfstoffplattform an, die einen rekombinanten Proteinansatz, eine fortschrittliche Nanopartikeltechnologie und sein patentiertes Adjuvans Matrix-M zur Verstärkung der Immunreaktion kombiniert.
3 小時前 · Novavax gains as US FDA to consider JN.1 variant for updated COVID shots. ** Shares of vaccine maker Novavax NVAX rise ~13% to $17.02 in early trading. ** U.S. Food and Drug Administration (FDA) staff reviewers say COVID-19 vaccine makers should consider targeting one of the currently dominant JN.1 variants and JN.1-derived sub-variants for ...
19 小時前 · 3 juin - ** Les actions du fabricant de vaccins Novavax NVAX.O augmentent d'environ 13 % à 17,02 $ dans les premiers échanges ** La Food and Drug Administration (FDA) () a déclaré que les ...
